Drug Profile
Alpha-1 antitrypsin biosimilar - Curaxys
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Curaxys
- Developer Curaxys; University of Cadiz
- Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Cystic-fibrosis in Spain
- 08 Jun 2015 Early research in Cystic fibrosis in Spain (unspecified route)